Neuca

Neuca EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Neuca (NEU.WA) as of Nov 14, 2026 is 11.41. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -130.08 — a change of -108.77% (higher).

EV/FCF

11.41

YoY

-108.77%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Neuca is 2025 11.41 . EV/FCF (Enterprise Value to Free Cash Flow) of Neuca was 2024 -130.08 . It decreases by -108.77% higher compared to the previous year.

The Neuca EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
316.45 PLN
Jan 1, 2019
48.57 PLN
Jan 1, 2020
15.48 PLN
Jan 1, 2021
14.72 PLN
Jan 1, 2022
14.57 PLN
Jan 1, 2023
21.12 PLN
Jan 1, 2024
-130.08 PLN
Jan 1, 2025
11.41 PLN
The Neuca EV/FCF history
YEAREV/FCFYoY
11.41-108.77%
-130.08-715.78%
21.12+44.97%
14.57-1.04%
14.72-4.90%
15.48-68.12%
48.57-84.65%
316.45+452.49%
57.28+104.44%
28.02+13.74%
24.63+9.06%
22.59—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

EV/FCF (Enterprise Value to Free Cash Flow) of Neuca is 11.41 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Neuca changed from -130.08 to 11.41, representing a -108.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Neuca since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Neuca with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neuca

All Key Metrics — Neuca